Marinus Jan Hagens

Marinus Jan Hagens

Auto-generated profile, based on publicly available information

Marinus Jan Hagens

Department of Urology, Netherlands Cancer Institute, 1066 Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2022 in European Urology Open Science
Verified
Journal Article
Open access
MHMarinus J. Hagens
Marinus J. Hagens
MSMar Fernandez Salamanca
Mar Fernandez Salamanca
APAnwar R. Padhani
Anwar R. Padhani
PLPim J. van Leeuwen
Pim J. van Leeuwen
HPHenk G. van der Poel
Henk G. van der Poel
ISIvo G. Schoots
Ivo G. Schoots
Systematic biopsies are additionally recommended to maximize the diagnostic performance of the magnetic resonance imaging (MRI) diagnostic pathway for men with suspected prostate cancer (PCa) and positive scans. To reduce unnecessary systematic biopsies (SBx), MRI-directed approaches comprising targeted plus regional biopsy (TBx + RBx) are being investigated. To systematically evaluate the diagnostic performance of MRI-directed TBx + RBx approaches in comparison to MRI-directed TBx alone and TBx + SBx approaches. The MEDLINE and Embase databases were searched according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses process. Identified reports were critically appraised according to the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria. Detection of grade group (GG) ≥2 PCa was the endpoint of interest. Fixed-effect meta-analyses were conducted to characterize summary effect sizes and quantify heterogeneity. Only MRI-positive men were included. A total of eight studies were included for analysis. Among a cumulative total of 2603 men with suspected PCa, the GG ≥2 PCa detection rate did not significantly differ between MRI-directed TBx + RBx and TBx + SBx approaches (risk ratio [RR] 0.95, 95% confidence interval [CI] 0.90–1.01; p = 0.09). The TBx + RBx results were obtained using significantly fewer biopsy cores and avoiding contralateral SBx altogether. By contrast, there was significant difference in GG ≥2 PCa detection between MRI-directed TBx + RBx and TBx approaches (RR 1.18, 95% CI 1.10–1.25; p < 0.001). MRI-directed TBx + RBx approaches showed a nonsignificant difference in detection of GG ≥2 PCa compared to the recommended practice of MRI-directed TBx + SBx. However, owing to the extensive heterogeneity among the studies included, future prospective clinical studies are needed to further investigate, optimize, and standardize this promising biopsy approach. We reviewed the scientific literature on prostate biopsy approaches using magnetic resonance imaging (MRI)-directed targeted biopsy plus regional biopsy of the prostate. The studies we identified found arguments to potentially embrace such a combined biopsy approach for future diagnostics in prostate cancer.

2 August 2022 in European Urology Open Science
Verified
Journal Article
Open access
MHMarinus J. Hagens
Marinus J. Hagens
MNM. Arjen Noordzij
M. Arjen Noordzij
JMJan Willem Mazel
Jan Willem Mazel
AJAuke Jager
Auke Jager
TBThierry N. Boellaard
Thierry N. Boellaard
SRSybren P. Rynja
Sybren P. Rynja
Considering that most men benefit diagnostically from increased sampling of index lesions, limiting systematic biopsy (SBx) to the region around the index lesion could potentially minimize overdetection while maintaining the detection of clinically significant prostate cancer (csPCa). To evaluate the diagnostic performance of a hypothetical magnetic resonance imaging (MRI)-directed targeted-plus-perilesional biopsy approach. This single-center, retrospective analysis of prospectively generated data included all biopsy-naïve men with unilateral MRI-positive lesions (Prostate Imaging Reporting and Data System category ≥3), undergoing both MRI-directed targeted biopsies and SBx. Grade group 2–5 cancers were considered csPCa. The diagnostic performance of a targeted-plus-perilesional biopsy approach was compared with that of a targeted-plus-systematic biopsy approach. The primary outcome was the detection of csPCa. Secondary outcomes included the detection of clinically insignificant prostate cancer (ciPCa) and the number of total biopsy cores. A total of 235 men were included in the analysis; csPCa and ciPCa were detected, respectively, in 95 (40.4%) and 86 (36.6%) of these 235 men. A targeted-plus-perilesional biopsy approach would have detected 92/95 (96.8%; 95% confidence interval [CI] 91.0–99.3%) csPCa cases. At the same time, detection of systematically found ciPCa would be reduced by 11/86 (12.8%; 95% CI 6.6–21.7%). If a targeted-plus-perilesional biopsy approach would have been performed, the number of biopsy cores per patient would have been reduced significantly (a mean difference of 5.2; 95% CI 4.9–5.6, p < 0.001). An MRI-directed targeted-plus-perilesional biopsy approach detected almost all csPCa cases, while limiting overdiagnosis and reducing the number of biopsy cores. Prospective clinical trials are needed to substantiate the withholding of nonperilesional SBx in men with unilateral lesion(s) on MRI. Limiting systematic biopsies to the proximity of the suspicious area on magnetic resonance imaging helps detect an equivalent number of aggressive cancers and fewer indolent cancers. These findings may help patients and physicians choose the best biopsy approach.

25 August 2022 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
MHMarinus Jan Hagens
Marinus Jan Hagens
DODaniela E. Oprea-Lager
Daniela E. Oprea-Lager
AVAndré N. Vis
André N. Vis
MWMaurits Wondergem
Maurits Wondergem
MDMaarten L. Donswijk
Maarten L. Donswijk
HPHenk G. van der Poel
Henk G. van der Poel
Purpose: To determine and compare the interobserver variability of three clinically frequently used radiotracers targeting the prostate specific membrane antigen (PSMA), namely 18F-DCFPyL, 18F-PSMA-1007 and 68Ga-PSMA-11, in primary prostate cancer (PCa) staging. Methods: Patients with newly diagnosed PCa in whom a PSMA-PET/CT was performed for primary staging purposes, were retrospectively included. All PSMA-PET/CT images were centrally overread within a high-volume PCa center and original reports (from referring hospitals) were compared to overread reports (from the overreading hospital). To assess the interobserver variability a Cohen’s kappa analysis was used. To study possible differences in interobserver variability between the three used PSMA-radiotracers, multivariate logistic regression analyses were used. Results: In total, 584 patients with newly diagnosed PCa were included in the analysis. 18F-DCFPyL, 18F-PSMA-1007 and 68Ga-PSMA-11 were undertaken in 205/584 (35.1%), 168/584 (28.8%) and 211/584 (36.1%) patients, respectively. The overall agreement (Cohen’s kappa analysis) for locoregional lymph-node metastases, distant lymph-node metastases, bone metastases and visceral metastases was 0.86, 0.86, 0.80 and 0.46, respectively. 18F-PSMA-1007 showed a significantly higher interobserver variability regarding bone metastases, compared to 18F-DCFPyL and 68Ga-PSMA-11 (P = 0.001 and P = 0.03, respectively). Additionally, 18F-PSMA-1007 showed a significantly higher interobserver variability regarding overall agreement and locoregional lymph-node metastases, compared to 18F-DCFPyL (p<0.001 and P = 0.01, respectively). Conclusion: The interobserver variability differs among the three clinically frequently used PSMA-radiotracers (18F-DCFPyL, 18F-PSMA-1007 and 68Ga-PSMA-11) in patients with newly diagnosed PCa. The agreement in bone metastases is significantly worse for 18F-PSMA-1007, mainly due to non-specific tracer uptake in osseous structures. Based on our findings, PSMA-PET/CT scans undertaken with 18F-PSMA-1007 in primary staging should be interpreted carefully and training in interpreting this specific PSMA-radiotracer is strongly advised.

2 September 2023 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
MHM. J. Hagens
M. J. Hagens
LRL. L. A. Ribbert
L. L. A. Ribbert
AJA. Jager
A. Jager
HVHans Veerman
Hans Veerman
KBK. Barwari
K. Barwari
HPH. G. van der Poel
H. G. van der Poel

16 October 2022 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
MHMarinus J. Hagens
Marinus J. Hagens
PSPiter J. Stelwagen
Piter J. Stelwagen
HVHans Veerman
Hans Veerman
SRSybren P. Rynja
Sybren P. Rynja
MSMartijn Smeenge
Martijn Smeenge
HPHenk G. van der Poel
Henk G. van der Poel

19 March 2023 in Life
Verified
Journal Article
Open access
PDF file
TBThierry N. Boellaard
Thierry N. Boellaard
MHMarinus J. Hagens
Marinus J. Hagens
HVHans Veerman
Hans Veerman
DYDerya Yakar
Derya Yakar
Laura S. MertensLaura S. Mertens
Laura S. Mertens
MHMargriet C. van Dijk-De Haan
Margriet C. van Dijk-De Haan
Prostate MRI has an important role in prostate cancer diagnosis and treatment, including detection, the targeting of prostate biopsies, staging and guiding radiotherapy and active surveillance. However, there are other ‘’less well-known’’ applications which are being studied and frequently used in our highly specialized medical center. In this review, we focus on two research topics that lie within the expertise of this study group: (1) anatomical parameters predicting the risk of urinary incontinence after radical prostatectomy, allowing more personalized shared decision-making, with special emphasis on the membranous urethral length (MUL); (2) the use of three-dimensional models to help the surgical planning. These models may be used for training, patient counselling, personalized estimation of nerve sparing and extracapsular extension and may help to achieve negative surgical margins and undetectable postoperative PSA values.